Vascular effects of PPARγ activators - From bench to bedside

Progress in Lipid Research

Volumn 46, Issue 6, 2007, Pages 283-296

  Marx, Nikolaus ^a   Walcher, Daniel ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Arteriosclerosis; Diabetes; Inflammation; PPAR ; Vascular cells

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID A PROTEIN; C REACTIVE PROTEIN; CD40 LIGAND; CIGLITAZONE; FENOFIBRATE; GELATINASE B; GEMFIBROZIL; GLIMEPIRIDE; LINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TELMISARTAN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOGENESIS; ATHEROGENESIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; EDEMA; ENDOTHELIAL DYSFUNCTION; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; INTIMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; RESTENOSIS; REVIEW; SIDE EFFECT; THROMBOGENESIS; TREATMENT OUTCOME; VASCULARIZATION; WEIGHT GAIN; ANIMAL; ARTERIOSCLEROSIS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CORONARY RESTENOSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 34748910218     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2007.05.003     Document Type: Review

References (137)

1. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators [see comments]. Nature 347 (1990) 645-650
2. Schoonjans K., Martin G., Staels B., and Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8 (1997) 159-166
3. Jia Y., Guo G.L., Surapureddi S., et al. Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity. Proc Natl Acad Sci USA 102 (2005) 12531-12536
4. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., and Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92 (1998) 829-839
5. Zhu Y., Kan L., Qi C., et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 275 (2000) 13510-13516
6. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., and Evans R.M. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
7. Xu H.E., Stanley T.B., Montana V.G., et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 (2002) 813-817
8. Pascual G., Fong A.L., Ogawa S., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763
9. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 (1997) 4312-4317
10. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
11. Ziouzenkova O., Perrey S., Asatryan L., et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 100 (2003) 2730-2735
12. Spiegelman B.M. PPARgamma: adipogenis regulator and thiazoledinedione receptor. Diabetes 1998 (1998) 507-514
13. Fajas L., Fruchart J.C., and Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol 10 (1998) 165-173
14. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8 (1994) 1224-1234
15. Yeh W.C., Cao Z., Classon M., and McKnight S.L. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev 9 (1995) 168-181
16. Schoonjans K., and Auwerx J. Thiazoledinediones: an update. The Lancet 355 (2000) 1008-1010
17. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
18. Nagy L., Tontonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (1998) 229-240
19. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
20. Benson S.C., Pershadsingh H.A., Ho C.I., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
21. Schupp M., Clemenz M., Gineste R., et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54 (2005) 3442-3452
22. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
23. Gilde A.J., van-der-Lee K.A., Willemsen P.H., et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92 (2003) 518-524
24. Leibowitz M.D., Fievet C., Hennuyer N., et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 473 (2000) 333-336
25. Oliver Jr. W.R., Shenk J.L., Snaith M.R., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98 (2001) 5306-5311
26. Wang Y.X., Lee C.H., Tiep S., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113 (2003) 159-170
27. Tanaka T., Yamamoto J., Iwasaki S., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100 (2003) 15924-15929
28. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
29. Norris A.W., Chen L., Fisher S.J., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112 (2003) 608-618
30. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
31. Campia U., Matuskey L.A., and Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113 (2006) 867-875
32. Samaha F.F., Szapary P.O., Iqbal N., et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 624-630
33. Szapary P.O., Bloedon L.T., Samaha F.F., et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 182-188
34. Winkler K., Konrad T., Fullert S., et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26 (2003) 2588-2594
35. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
36. Sakamoto J., Kimura H., Moriyama S., et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
37. Fullert S., Schneider F., Haak E., et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 87 (2002) 5503-5506
38. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
39. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
40. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., and Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92 (1995) 3893-3897
41. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
42. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
43. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19 (1999) 546-551
44. Marx N., Kehrle B., Kohlhammer K., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90 (2002) 703-710
45. Marx N., Schönbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 (1998) 1097-1103
46. Marx N., Sukhova G., Murphy C., Libby P., and Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153 (1998) 17-23
47. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95 (1998) 7614-7619
48. Yang X.Y., Wang L.H., Chen T., et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275 (2000) 4541-4544
49. Calabro P., Samudio I., Safe S.H., Willerson J.T., and Yeh E.T. Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects. J Vasc Res 42 (2005) 509-516
50. Marx N., Mach F., Sauty A., et al. PPARg activators inhibit Interferon-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164 (2000) 6503-6508
51. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
52. Sasaki M., Jordan P., Welbourne T., et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol 5 (2005) 3
53. Verrier E., Wang L., Wadham C., et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 94 (2004) 1515-1522
54. Marx N., Sukhova G., Collins T., Libby P., and Plutzky J. PPARa activators inhibit cytokine-induced vascular cell adhesion molecule 1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
55. Delerive P., Martin-Nizard F., Chinetti G., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 (1999) 394-402
56. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 52-57
57. Ptasinska A., Wang S., Zhang J., Wesley R.A., and Danner R.L. Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway. Faseb J 21 (2007) 950-961
58. Hwang J., Kleinhenz D.J., Lassegue B., Griendling K.K., Dikalov S., and Hart C.M. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288 (2005) C899-C905
59. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50 (2001) 3-11
60. Bishop Bailey D., and Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 274 (1999) 17042-17048
61. Artwohl M., Holzenbein T., Furnsinn C., et al. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost 93 (2005) 810-815
62. Hannan K.M., Dilley R.J., de Dios S.T., and Little P.J. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol 23 (2003) 762-768
63. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
64. Shu H., Wong B., Zhou G., et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 267 (2000) 345-349
65. Oyama Y., Akuzawa N., Nagai R., and Kurabayashi M. PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circ Res 90 (2002) 348-355
66. Oyama Y., Kurabayashi M., Akuzawa N., and Nagai R. Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/macrophage THP-1 cells. J Atheroscler Thromb 7 (2000) 77-82
67. Akiyama T.E., Sakai S., Lambert G., et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22 (2002) 2607-2619
68. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
69. Chawla A., Boisvert W.A., Lee C.H., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (2001) 161-171
70. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
71. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
72. Hou M., Xia M., Zhu H., et al. Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells via PPARgamma-LXRalpha-ABCA1-dependent pathway associated with apoE. Cell Biochem Funct 25 (2007) 33-44
73. Haraguchi G., Kobayashi Y., Brown M.L., et al. PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage poB-48 receptor. J Lipid Res 44 (2003) 1224-1231
74. Clark R.B., Bishop Bailey D., Estrada Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164 (2000) 1364-1371
75. Faveeuw C., Fougeray S., Angeli V., et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 486 (2000) 261-266
76. Bishop-Bailey D., Hla T., and Warner T.D. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res 91 (2002) 210-217
77. de-Dios S.T., Bruemmer D., Dilley R.J., et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107 (2003) 2548-2550
78. Kihara S., Ouchi N., Funahashi T., et al. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 136 (1998) 163-168
79. Wakino S., Kintscher U., Kim S., Yin F., Hsueh W.A., and Law R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells. J Biol Chem 275 (2000) 22435-22441
80. Bruemmer D., Berger J.P., Liu J., et al. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 466 (2003) 225-234
81. Goetze S., Xi X.P., Kawano H., et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells [In Process Citation]. J Cardiovasc Pharmacol 33 (1999) 798-806
82. Goetze S., Xi X.P., Kawano Y., et al. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 33 (1999) 183-189
83. Zahradka P., Wright B., Fuerst M., Yurkova N., Molnar K., and Taylor C.G. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J Pharmacol Exp Ther 317 (2006) 651-659
84. Game B.A., Maldonado A., He L., and Huang Y. Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism. Atherosclerosis 178 (2005) 249-256
85. Schiffrin E.L., Amiri F., Benkirane K., Iglarz M., and Diep Q.N. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 42 (2003) 664-668
86. Takeda K., Ichiki T., Tokunou T., et al. Peroxisome proliferator-activated receptor activators downregulate Angiotensin II Type 1 receptor in vascular smooth muscle cells. Circulation 102 (2000) 1834-1839
87. Akbiyik F., Ray D.M., Gettings K.F., Blumberg N., Francis C.W., and Phipps R.P. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104 (2004) 1361-1368
88. Li D., Chen K., Sinha N., et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65 (2005) 907-912
89. Ray D.M., Akbiyik F., and Phipps R.P. The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. J Immunol 177 (2006) 5068-5076
90. Ray D.M., Spinelli S.L., O'Brien J.J., Blumberg N., and Phipps R.P. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs 20 (2006) 231-241
91. Gaillard V., Casellas D., Seguin-Devaux C., et al. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 46 (2005) 372-379
92. Nicol C.J., Adachi M., Akiyama T.E., and Gonzalez F.J. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 18 (2005) 549-556
93. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
94. Wang J., Sim A.S., Wang X.L., and Wilcken D.E. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci 63 (2006) 2838-2846
95. Tao L., Liu H.R., Gao E., et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 108 (2003) 2805-2811
96. Gensch C., Clever Y.P., Werner C., Hanhoun M., Bohm M., and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis (2006)
97. Wang C.H., Ciliberti N., Li S.H., et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109 (2004) 1392-1400
98. Collins A.R., Meehan W.P., Kintscher U., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 365-371
99. Li A.C., Binder C.J., Gutierrez A., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114 (2004) 1564-1576
100. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
101. He L., Game B.A., Nareika A., Garvey W.T., and Huang Y. Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques. J Cardiovasc Pharmacol 48 (2006) 212-222
102. Wang Z.H., Luo F., and Liu X.M. [Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits]. Yao Xue Xue Bao 40 (2005) 1051-1053
103. Law R.E., Meehan W.P., Xi X.P., et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98 (1996) 1897-1905
104. Igarashi M., Takeda Y., Ishibashi N., et al. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm Metab Res 29 (1997) 444-449
105. Lim S., Jin C.J., Kim M., et al. PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 26 (2006) 808-813
106. Joner M., Farb A., Cheng Q., et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27 (2007) 182-189
107. Tanaka T., Fukunaga Y., Itoh H., et al. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol 508 (2005) 255-265
108. Koenig W., and Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 27 (2007) 15-26
109. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
110. Shimizu H., Oh I.S., Tsuchiya T., Ohtani K.I., Okada S., and Mori M. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabet Med 23 (2006) 253-257
111. Esposito K., Ciotola M., Carleo D., et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29 (2006) 1071-1076
112. Marx N., Froehlich J., Siam L., et al. The antidiabetic PPARg-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscl Thromb Vasc Biol 23 (2003) 283-288
113. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
114. Sidhu J.S., Cowan D., and Kaski J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42 (2003) 1757-1763
115. Marx N., Froehlich J., Siam L., et al. Effect of rosiglitazone treatment on soluble CD40L in type-2 diabetic patients with coronary artery disease. Circulation 107 (2003) 1954-1957
116. Hetzel J., Balletshofer B., Rittig K., et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25 (2005) 1804-1809
117. Hanefeld M., Marx N., Pfutzner A., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol 49 (2007) 290-297
118. Bahia L., Aguiar L.G., Villela N., et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis (2006)
119. Ryan K.E., McCance D.R., Powell L., McMahon R., and Trimble E.R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis (2006)
120. Martens F.M., Rabelink T.J., op 't Roodt J., de Koning E.J., and Visseren F.L. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 27 (2006) 1605-1609
121. Sourij H., Zweiker R., and Wascher T.C. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29 (2006) 1039-1045
122. Suzuki M., Takamisawa I., Yoshimasa Y., and Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract 76 (2007) 12-17
123. Wang T.D., Chen W.J., Cheng W.C., Lin J.W., Chen M.F., and Lee Y.T. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98 (2006) 1057-1062
124. Staniloae C., Mandadi V., Kurian D., et al. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 108 (2006) 164-169
125. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128 (1998) 262-269
126. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. Jama 296 (2006) 2572-2581
127. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (2004) 930-934
128. Takagi T., Yamamuro A., Tamita K., et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 89 (2002) 318-322
129. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
130. Marx N., Wöhrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation 112 (2005) 2792-2798
131. Meisner F., Walcher D., Gizard F., et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 26 (2006) 845-850
132. Marfella R., D'Amico M., Di Filippo C., et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol 47 (2006) 2444-2455
133. Marfella R., D'Amico M., Esposito K., et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55 (2006) 622-632
134. Dormandy J.A., Charbonnel B., Eckland D.J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
135. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
136. Hollenberg N.K. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115 Suppl 8A (2003) 111S-115S
137. Rennings A.J., Smits P., Stewart M.W., and Tack C.J. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 29 (2006) 581-587